Peter Wittner is an independent consultant.
Biosimilars: Is It Worth Taking On The Regulators?
The different pathways to regulatory approval of a biosimilar vary worldwide, ranging from no pathways at all in some developing countries, to the complex and precise mechanism that exists in Europe.